Primary myelofibrosis and its paraneoplastic stromal effects.
Tefferi
Ayalew
A
D019943:Amino Acid Substitution; D000818:Animals; D015551:Autoimmunity; D002999:Clone Cells / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005355:Fibrosis; D006411:Hematopoiesis, Extramedullary; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics / Q000502:physiology; D051379:Mice; D009196:Myeloproliferative Disorders / Q000145:classification* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000503:physiopathology; D010257:Paraneoplastic Syndromes / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D020286:Pericytes / Q000473:pathology*; D010641:Phenotype; D017354:Point Mutation; D055728:Primary Myelofibrosis / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D053628:Receptors, Thrombopoietin / Q000235:genetics / Q000502:physiology; D017154:Stromal Cells / Q000276:immunology / Q000473:pathology; D009626:Terminology as Topic
D016207:Cytokines; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; C507924:JAK2 protein, human; C507926:Jak2 protein, mouse; D053614:Janus Kinase 2